BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vidofludimus: Preliminary Phase IIa data

Preliminary data from the open-label, single-arm, international Phase IIa ENTRANCE trial in 26 evaluable corticosteroid-dependent patients with Crohn's disease or ulcerative colitis (UC) showed that once-daily 35 mg oral vidofludimus for 12 weeks met the primary endpoint of significantly increasing response...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >